<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884182</url>
  </required_header>
  <id_info>
    <org_study_id>GPA12</org_study_id>
    <nct_id>NCT00884182</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children</brief_title>
  <official_title>Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is part of an effort to develop an effective vaccination program in children in&#xD;
      the event of a pandemic.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
        -  To describe the safety profiles in the periods following each vaccination in subjects&#xD;
           receiving different vaccination schedule.&#xD;
&#xD;
        -  To describe the immune response after each vaccination in subjects receiving study&#xD;
           vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive two administrations of the investigational vaccine at one of&#xD;
      3 vaccination schedules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety of the Split Virion Pandemic Influenza vaccine.</measure>
    <time_frame>21 days post-vaccination and entire study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide information concerning the immunogenicity of Split Virion Pandemic Influenza vaccine.</measure>
    <time_frame>21 days post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Influenza</condition>
  <condition>Orthomyxoviridae Infections</condition>
  <condition>Orthomyxovirus Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on vaccination schedule 1 (Day 0 and Day 21)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on vaccination schedule 2 (Day 0 and Day 14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on vaccination schedule 3 (Day 0 and Day 42)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
        All Subjects&#xD;
&#xD;
          -  Subject and parent(s)/legal representative able to attend all scheduled visits and to&#xD;
             comply with all trial procedures.&#xD;
&#xD;
          -  Completion of vaccination according to the national immunization schedule&#xD;
&#xD;
        Subjects Aged ≥ 2 Years to &lt; 18 Years:&#xD;
&#xD;
          -  Aged ≥ 2 years to &lt; 18 years on the day of inclusion.&#xD;
&#xD;
          -  Provision of Informed Consent Form signed by the subject's the parent(s)/legal&#xD;
             representative (and by an independent witness if required by local regulations). In&#xD;
             addition, provision of Assent Form signed by subjects aged 8 to 11 years, and of&#xD;
             Informed Consent Form signed by subjects ≥ 12 years.&#xD;
&#xD;
          -  For a female of child-bearing potential, avoid becoming pregnant (use of an effective&#xD;
             method of contraception or abstinence) for at least 4 weeks prior to each vaccination,&#xD;
             until at least 4 weeks after each vaccination.&#xD;
&#xD;
        Subjects Aged ≥ 6 Months to &lt; 2 Years:&#xD;
&#xD;
          -  Aged ≥ 6 months to &lt; 2 years on the day of inclusion.&#xD;
&#xD;
          -  Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg.&#xD;
&#xD;
          -  Provision of Informed Consent Form signed by the parent(s) or other legal&#xD;
             representative (and by an independent witness if required by local regulations).&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  Participation in another clinical trial investigating a vaccine, drug, medical device,&#xD;
             or a medical procedure in the 4 weeks preceding trial vaccination&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy&#xD;
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,&#xD;
             or long-term systemic corticosteroids therapy&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the vaccine components or history of a&#xD;
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the&#xD;
             same substances&#xD;
&#xD;
          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability&#xD;
             to comply with trial procedures&#xD;
&#xD;
          -  Receipt of Blood or blood-derived products in the past 3 months, that might interfere&#xD;
             with the assessment of immune response&#xD;
&#xD;
          -  Receipt of any vaccine in the 4 weeks preceding trial vaccination&#xD;
&#xD;
          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination&#xD;
&#xD;
          -  (Known) Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen or&#xD;
             Hepatitis C seropositivity&#xD;
&#xD;
          -  Previous vaccination against avian influenza with either the trial vaccine or another&#xD;
             vaccine&#xD;
&#xD;
          -  Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding&#xD;
             inclusion contraindicating IM vaccination&#xD;
&#xD;
          -  Subjects deprived of freedom by an administrative or court order, or in an emergency&#xD;
             setting, or hospitalized without his/her consent&#xD;
&#xD;
          -  Received oral or injected antibiotic therapy within the 72 hours prior to any blood&#xD;
             draw&#xD;
&#xD;
        Subjects Aged ≥2 Years to &lt;18 Years:&#xD;
&#xD;
          -  For a female of child-bearing potential, known pregnancy or positive urine pregnancy&#xD;
             test&#xD;
&#xD;
          -  Breast-feeding female&#xD;
&#xD;
          -  Febrile illness (temperature ≥ 37.5 °C) or moderate or severe acute illness/infection&#xD;
             on the day of vaccination, according to investigator judgment&#xD;
&#xD;
        Subjects Aged ≥ 6 Months to &lt; 2 Years:&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Febrile illness (temperature ≥ 38 °C) or moderate or severe acute illness/infection on&#xD;
             the day of vaccination, according to investigator judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Espoo</city>
        <zip>FIN-02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Järvenpää</city>
        <zip>FIN-04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <zip>FIN-70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahti</city>
        <zip>FIN-15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>FIN-90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pori</city>
        <zip>FIN-28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>FIN-33014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>FIN-33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vantaa</city>
        <zip>FIN-01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vantaa</city>
        <zip>FIN-01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Split Virion Pandemic Influenza Vaccine</keyword>
  <keyword>A/H5N1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

